# Can Ipamorelin improve lean body mass in cancer cachexia?

Canonical source: https://retacompare.com/research/can-ipamorelin-improve-lean-body-mass-in-cancer-cachexia

Peptide Longevity Q&A · 2021-02-01


    Ipamorelin, as a ghrelin receptor agonist, has shown potential in improving lean body mass in patients with cancer cachexia. In clinical trials, significant increases in lean body mass were observed in patients with non-small cell lung cancer and other gastrointestinal cancers.

 What the research shows

The study focuses on the regulatory approval of anamorelin, a ghrelin receptor agonist, for treating cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan. The research indicates that anamorelin can be administered orally and is thought to enhance appetite while increasing serum insulin-like growth factor-1 (IGF-1), which is crucial for muscle growth. In a Phase 2 trial (ONO-7643-04) involving patients with non-small cell lung cancer and cachexia, a notable increase of 1.56 kg in lean body mass was recorded, assessed through dual-energy X-ray absorptiometry (DXA). Another study involving advanced gastrointestinal cancers showed an average improvement of 1.89 ± 0.36 kg in lean body mass. These findings highlight the importance of addressing cachexia, which has historically been underdiagnosed in Japan, often misconceived as a terminal condition.

 Why it matters for longevity

The implications of enhancing lean body mass through treatments like Ipamorelin are significant for longevity and overall healthspan. Cachexia is a debilitating condition that affects many cancer patients, leading to muscle wasting and decreased quality of life. By improving lean body mass, treatments like anamorelin could potentially enhance physical function, resilience, and overall well-being in aging populations and those suffering from chronic illnesses. This is particularly relevant as maintaining muscle mass is crucial for metabolic health, mobility, and reducing the risk of frailty and other age-related conditions.

 Key findings at a glance

Anamorelin is a ghrelin receptor agonist approved in Japan for cancer cachexia.

It was shown to improve appetite and increase serum IGF-1 levels.

In clinical trials, patients with non-small cell lung cancer experienced a 1.56 kg increase in lean body mass.

Patients with advanced gastrointestinal cancers had an average improvement of 1.89 ± 0.36 kg in lean body mass.

Cachexia has been historically underdiagnosed in Japan, often associated with terminal illness.

 How Ipamorelin works (background)

Ipamorelin functions as a ghrelin receptor agonist, mimicking the action of ghrelin, a hormone that stimulates appetite and promotes growth hormone release. This mechanism is particularly beneficial in counteracting cachexia, as it not only encourages food intake but also enhances anabolic processes in the body, leading to increased muscle mass. The elevation of IGF-1 levels is critical because IGF-1 plays a significant role in muscle development and repair. By targeting these pathways, Ipamorelin may help mitigate the effects of muscle wasting in cancer patients and potentially in aging populations.

 Safety, caveats, and what we don't yet know

While the studies indicate promising results for Ipamorelin in improving lean body mass, further research is needed to fully understand its long-term safety, especially in older adults or those with multiple comorbidities. The current findings are primarily based on specific cancer populations, and additional studies are necessary to determine its efficacy and safety across broader demographics. Potential side effects and interactions with other medications have not been extensively studied, necessitating caution in clinical application.

 Bottom line

Ipamorelin shows promise in improving lean body mass in patients with cancer cachexia, potentially benefiting longevity and healthspan. Further research is needed to establish its long-term safety and efficacy across various populations.

 Related questions

 Does Ipamorelin enhance muscle recovery in aging individuals?

Research indicates that Ipamorelin may improve muscle recovery by promoting lean body mass increase, which is crucial for aging individuals. However, specific studies targeting this demographic are still needed.

 How does Ipamorelin compare to other peptides for muscle growth?

Ipamorelin is unique as a ghrelin receptor agonist, differing from other peptides like growth hormone-releasing peptides. Its specific mechanism may offer distinct advantages in appetite stimulation and muscle preservation.

 What are the potential side effects of Ipamorelin?

While Ipamorelin is generally well-tolerated, potential side effects could include gastrointestinal discomfort or changes in appetite. More extensive research is required to identify and understand all possible side effects.

 Source: PubMed · J Cachexia Sarcopenia Muscle · published 2021-02-01.

## Sources

- PubMed · J Cachexia Sarcopenia Muscle: https://pubmed.ncbi.nlm.nih.gov/33382205/